ARI-0001 cells

Phase 2Small molecule

SSara V. Latorre

ARI-0001 cells is one of 19 small molecule programs targeting Lymphoid Leukemia. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Lymphoid LeukemiaActive, not recruiting

Lymphoid LeukemiaPhase 2

Active, not recruiting

Competition

Competitive Landscape

19 competitors in Lymphoid Leukemia

#DrugCompanyPhaseTrials

Arranon

Adriamycin

Cytosar

Thalomid

Iclusig

Imbruvica

Purinethol

Decadron

AAspen Global Incorporated

Coreg

Vidaza

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Lymphoid Leukemia1 trial

Study of the Infusion of ARI-0001 Cells in Patients With CD19 + Acute Lymphoid Leukemia Resistant or Refractory to Therapy

Active, not recruiting·SSara V. Latorre·Phase 2·NCT04778579·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for ARI-0001 cells. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ARI-0001 cells compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ARI-0001 cells. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sara V. Latorre company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SSara V. Latorre

ARI-0001 cells

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Lymphoid Leukemia1 trial

References

Drug Info

Quick Facts

Related News